Vance Street Capital has acquired Prince Sterilization Services, a provider of contract medical device sterilization services. This acquisition marks Vance Street’s second Fund IV platform and its 15th investment in the life sciences and medical sector.
Prince offers a range of sterilization services, including steam, dry heat, vaporized hydrogen peroxide (VHP), depyrogenation (the removal of fever-causing substances), and water for injection (WFI) rinsing. The company also supplies ready-to-use (RTU) drug containment products, such as vials, bottles, stoppers, and seals.
Prince’s VHP service utilizes a low-temperature antimicrobial vapor for decontaminating and sterilizing enclosed spaces, surfaces, and medical devices, effectively destroying microbial life. In January 2024, the FDA classified VHP as an “Established Category A” sterilization method for medical devices, underscoring its safety and effectiveness. Prince’s WFI product, a highly purified and sterile water, is used in the pharmaceutical industry for producing injectable drugs and rinsing medical devices.
Prince serves a diverse customer base, including pharmaceutical, biotechnology, compounding pharmacy, and medical device companies. The company, founded by Dr. Daniel Prince, who serves as CEO, is headquartered in Pine Brook, New Jersey, near Newark, with an additional facility in Fairfield. Dr. Derek Prince, the founder’s son, is the company’s president. Under the partnership with Vance Street, Daniel and Derek will retain significant ownership in Prince and will continue managing daily operations.
“The Prince family has built a terrific organization, and we look forward to supporting their continued growth,” said Steve Sandbo, a partner at Vance Street. “Prince’s focus on eco-friendly sterilization services and products across the pharmaceutical and medical device markets is a great fit with our past investing experience. We are excited to partner with Prince to support the ongoing buildout of additional capabilities and capacity to serve their growing customer base.”
“We are excited about the next chapter of growth and our partnership with Vance Street. Their support will enable us to expand our capabilities and offerings and maintain our commitment to providing innovative and reliable sterilization solutions to our valued customers,” said Derek Prince.
This acquisition is the second platform investment for Vance Street’s Fund IV, following the September 2024 acquisition of Pro-Vision, a Michigan-based provider of video monitoring products and services for commercial, K-12 transit, and public safety sectors. Vance Street’s fourth fund closed at its hard cap of $775 million in May 2024.
“Prince is a great representation of our strategy of partnering with founder-owned businesses in critical markets, such as pharma, biopharma, and medical devices. We are excited to support Prince’s management in developing new growth opportunities, including broadening their product portfolio and services to meet an evolving market’s needs,” said Grady Miller, a principal at Vance Street.
Vance Street, headquartered in Pacific Palisades, Los Angeles, makes control investments in North American companies with enterprise values between $30 million and $350 million and EBITDA of $3 million to $30 million. Key sectors include medical technology, life sciences, industrial technology, and aerospace & defense.
Capstone Partners served as the financial advisor to Prince, and Paul Hastings provided legal advisory to Vance Street. Debt financing for the transaction was provided by Apogem Capital and Bank of Montreal.
© 2024 Private Equity Professional | November 14, 2024
Branford Castle Partners has acquired Testek Solutions, a manufacturer of aviation component testing equipment, from Odyssey Investment Partners.
“We are excited to partner with Bruce and the entire Testek team,” said Eric Korsten, a senior managing director at Branford Castle. “We see attractive opportunities in this market as the aerospace industry continues to expand, creating increased demand for Testek’s specialized aviation testing equipment. The company’s leading position in the market, along with its proprietary capabilities, make it a terrific platform for growth.”
Branford Castle focuses on investing in companies with enterprise values up to $100 million and EBITDA of less than $15 million. The firm’s preferred sectors include industrials and specialty manufacturing, consumer products and services, commercial distribution, business services, and logistics. Founded in 1986, President and CEO John S. Castle and Managing Partner David Castle have led Branford Castle for the past 16 years. In addition to its New York City headquarters, the firm also operates an office in Boca Raton, Florida.
Transom Capital Group has held a final close of Transom Capital Fund IV LP with $675 million in capital commitments. Fund IV closed above its target and initial hard cap and is more than double the size of the firm’s third fund.
“The oversubscribed closing of Fund IV marks a significant milestone for Transom and we believe is reflective of our 16-year track record and dedication to our longstanding, consistent strategy of creating value through operational improvements in the middle market,” said Russ Roenick, a co-founder and managing partner at 
“Fund IV is off to a tremendous start with our team having already closed three platform investments, all of which we believe are positioned to perform strongly, and we have an expanding pipeline of promising future opportunities,” said Ken Firtel, a co-founder and managing partner at Transom.
Godspeed Capital Management has finalized an oversubscribed, hard-cap close of Godspeed Capital Fund III LP with $675 million in capital commitments. Godspeed initiated and completed fundraising within two months.
“We are thrilled with the strong support we have received from both existing and new investors for Fund III,” said Douglas Lake, Jr., founder and managing partner of 
As an example of this strategy, Godspeed’s portfolio company 
